Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

被引：10

作者：

Chong, Elise A. ^{[1
]}

Gerson, James N. ^{[1
]}

Landsburg, Daniel J. ^{[1
]}

Nasta, Sunita Dwivedy ^{[1
]}

Svoboda, Jakub ^{[1
]}

Porter, David L. ^{[1
]}

Dengel, Karen ^{[2
]}

Siegel, Don L. ^{[3
]}

Gilmore, Joan ^{[4
]}

Barta, Stefan K. ^{[5
]}

Levine, Bruce L. ^{[4
]}

June, Carl H. ^{[3
]}

Schuster, Stephen J. ^{[1
]}

机构：

[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[2] Univ Penn, Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[3] Univ Penn, Perelman ch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[4] Univ Penn, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[5] Univ Penn, Lymphoma Dept, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

关键词：

D O I：

10.1182/blood-2019-131078

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

594

引用

页数：4